The in vitro bleeding time while using a stable prostacyclin analogue during hemodialysis

Area of Science:

• Nephrology
• Hematology
• Pharmacology

Background:

• Preventing clot formation during dialysis often uses prostacyclin (PGI2) to inhibit platelet function.
• A significant limitation is the lack of a rapid monitoring parameter for PGI2's anticoagulant effects.
• Primary hemostasis assessment is crucial for managing bleeding risks.

Purpose of the Study:

• To evaluate the utility of the "in vitro bleeding time" (in vitro BT) as a monitoring parameter for anticoagulation during dialysis.
• To compare the effects of conventional heparinization versus a prostacyclin (PGI2) analogue (CG 4203) with low-dose heparin on hemostasis.
• To assess the concentration-dependent effects of CG 4203 on primary hemostasis.

Main Methods:

• A novel "in vitro bleeding time" (in vitro BT) assay was employed to measure primary hemostasis.
• Five chronic dialysis patients participated in a crossover study, undergoing two dialysis sessions.
• Session 1: Conventional full heparinization. Session 2: Stable PGI2 analogue CG 4203 with low-dose heparin.

Main Results:

• The predialytic in vitro BT was significantly longer than post-dialysis values.
• Conventional heparinization showed no significant impact on the in vitro BT.
• CG 4203 demonstrated a concentration-dependent prolongation of the in vitro BT, extending beyond 800 microliters at a 25 ng/kg/min infusion rate initially, then decreasing over time.

Conclusions:

• The "in vitro bleeding time" (in vitro BT) serves as a valuable and rapidly measurable monitoring parameter for primary hemostasis during dialysis.
• Prostacyclin (PGI2) analogue CG 4203 significantly impacts primary hemostasis in a concentration-dependent manner during dialysis.
• CG 4203 offers a potential alternative to heparin, with the in vitro BT enabling effective monitoring of its anticoagulant effects.